The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.
Brodt HR, Kamps BS, Gute P., Knupp B., Staszewski S., Helm EBChanging incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738.
2.
Michaels SH, Clark R., Kissinger P.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:405-406.
3.
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med.1998;338: 853-860.
4.
Sepkowitz KAEffect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 1998;351: 228-230.
5.
Detels R., Munoz A., McFarlane G., et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280: 1497-1503.
6.
Kaplan JE, Hanson D., Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
7.
Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17-26.
8.
Valdez H., Chowdhry TK, Asaad R., et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis. 2001;32:1487-1493.
9.
Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
10.
Carr A., Samaras K., Chisholm DJ, Cooper DAPathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
11.
Lo JC, Mulligan K., Tai VW, Algren H., Schambelan M.`Buffalo hump` in men with HIV-1 infection. Lancet . 1998;351:867-870.
12.
Viraben R., Aquilina C.Indinavir-associated lipodystrophy. AIDS. 1998;12:F37-F39.
13.
Garg A.Acquired and inherited lipodystrophies. N Engl J Med . 2004;350:1220-1234.
14.
Barbaro G.Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des. 2007;13:2208-2213.
15.
Qiao Q., Gao W., Zhang L., Nyamdorj R., Tuomilehto J.Metabolic syndrome and cardiovascular disease. Ann Clin Biochem . 2007;44(pt 3):232-263.
16.
Chen D., Misra A., Garg A.Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87:4845-4856.
17.
Wohl DA, McComsey G., Tebas P., et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43:645-653.
18.
Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003;34:461-466.
19.
Jacobson DL , Knox T., Spiegelman D., Skinner S., Gorbach S., Wanke C.Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women . Clin Infect Dis. 2005;40:1837-1845.
20.
Grinspoon S. , Carr A.Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005 ;352:48-62.
21.
Lichtenstein K., Balasubramanyam A., Sekhar R., Freedland E.HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms . AIDS Res Ther. 2007;4:14.
22.
Lichtenstein KARedefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.
Andrade S., Lan SJ, Engelson ES, et al. Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr. 2002;75:587-592.
25.
Carr A., Law M.An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33:571-576.
26.
Law M., Puls R., Cheng AK, Cooper DA, Carr A.Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther . 2006;11:179-186.
27.
Guaraldi G. , Orlando G., Squillace N., et al. Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr. 2007;45: 72-76.
28.
Palella FJ Jr, Chmiel JS, Riddler SA, et al. A novel pattern of lipoaccumulation in HIV-infected men. JAMA. 2006;296:766-768.
29.
Bacchetti P. , Gripshover B., Grunfeld C., et al. Fat distribution in men with HIV infection . J Acquir Immune Defic Syndr. 2005;40:121-131.
30.
Dinges WL, Chen D., Snell PG, Weatherall PT, Peterson DM, Garg A.Regional body fat distribution in HIV-infected patients with lipodystrophy . J Investig Med. 2005;53:15-25.
31.
Bacchetti P. , Cofrancesco J., Heymsfield S., et al. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006 ;42:562-571.
32.
Mulligan K. , Parker RA, Komarow L., et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr . 2006;41:590-597.
33.
Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
34.
Cossarizza A. , Riva A., Zanone Poma B., et al. FASl-670 and APOC3 polymorphisms as predictors of lipoatrophy in patients receiving ART. In: 13th Conference on Retroviruses and Opportunistic Infections (CROI) . Denver, CO; 2006.
35.
De Luca A. , Di Giambenedetto S., Schwarz J., et al. The effect of polymorphism of the MDR-1 gene on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected patients starting ART. In: 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO; 2006.
36.
Hulgan T., Tebas P., Canter J., et al. The H63D hemochromatosis (HFE) gene polymorphism and mitochondrial haplogroup J are associated with limb fat changes after initiation of ART: ACTG study A5005s. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007.
37.
Giralt M., Domingo P., Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther. 2006;11:729-740.
38.
Gougeon ML, Penicaud L., Fromenty B., Leclercq P., Viard JP, Capeau J.Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther. 2004 ;9:161-177.
39.
Kershaw EE, Flier JSAdipose tissue as an endocrine organ. J Clin Endocrinol Metab . 2004;89:2548-2556.
40.
Nolan D., Mallal S.Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004;9: 849-863.
41.
McComsey GA, Walker UARole of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion. 2004 ;4:111-118.
42.
Sekhar RV, Jahoor F., White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab. 2002;283:E332-E337.
43.
Balasubramanyam A., Sekhar RV, Jahoor F., Jones PH, Pownall HJPathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis' . Curr Opin Lipidol. 2004;15: 59-67.
44.
Pacenti M., Barzon L., Favaretto F., et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS. 2006 ;20:1691-1705.
45.
Vernochet C. , Azoulay S., Duval D., Guedj R., Ailhaud G., Dani C.Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation . AIDS. 2003;17:2177-2180.
46.
Grigem S., Fischer-Posovszky P., Debatin KM, Loizon E., Vidal H., Wabitsch M.The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes . Horm Metab Res. 2005;37:602-609.
47.
Cavalcanti R. , Kain K., Shen S., Raboud J., Walmsley S.A randomized placebo controlled trial of rosiglitazone for the treatment of HIV lipodystrophy . In: 12th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2005 .
48.
Mallon P., Sedwell R., Rogers G., et al. The effect of rosiglitazone on PPARg expression in human adipose tissue is limited by continued exposure to thymidine NRTI. In: 12th Conference on Retroviruses and Opportunistic Infections (CROI) . Boston, MA; 2005.
49.
El Hadri K. , Glorian M., Monsempes C., et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem.2004;279:15130-15141.
50.
Vigouroux C. , Maachi M., Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
51.
Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E261-E271.
52.
Bastard JP, Caron M., Vidal H., et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-1031.
53.
Tsiodras S. , Mantzoros C.Leptin and adiponectin in the HIV associated metabolic syndrome: physiologic and therapeutic implications. Am J Infect Dis. 2006;2: 141-152.
54.
Nagy GS, Tsiodras S., Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795-802.
55.
Sutinen J., Korsheninnikova E., Funahashi T., Matsuzawa Y., Nyman T., Yki-Jarvinen H.Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab. 2003 ;88:1907-1910.
56.
Sutinen J., Kannisto K., Korsheninnikova E., et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue . Diabetologia. 2004;47:1668-1671.
57.
Rietschel P. , Hadigan C., Corcoran C., et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy . J Clin Endocrinol Metab. 2001;86:504-510.
58.
Koutkia P., Canavan B., Breu J., Grinspoon S.Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab. 2005;90:32-38.
59.
Jemsek JG, Arathoon E., Arlotti M., et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis.2006 ;42:273-280.
60.
McComsey GA, Rightmire A., Wirtz V., Yang R., Mathew M., McGrath D.Body composition changes in ARVnaive subjects treated with atazanavir or atazanavir/ ritonavir-based once-daily HAART: 96-week CT and DEXA data In: 11th European AIDS Conference (EACS). Madrid , Spain; 2007.
61.
van Vonderen MGA , Blumer RME, Hassink E., et al. Persistent reduction in peripheral glucose disposal starting prior to fat distribution changes, only during first line ART with ZDV/3TC/LPV/r but not NVP/ LPV/r, suggests contribution of ZDV/3TC to insulin resistance by a body composition independent mechanism. In: 4th International AIDS Society Conference. Sydney, Australia; 2007.
62.
Haubrich R., Riddler S., DiRienzo G., et al. Metabolic outcomes of ACTG 5142: a prospective, randomized phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1. In: 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, CA; 2007.
63.
DHHS Panel on antiretroviral guidelines for adults and adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2006; 2007 (February 26, 2007).
64.
Hammer SM, Saag MS, Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296: 827-843.
65.
Gallant J., Pozniak A., Staszewski S., et al. Efficacy and safety of tenofovir-containing vs non-tenofovir-containing regimens in black ART-naive patients. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007.
66.
Gallant JE, Staszewski S., Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
67.
Dubé MP , Parker RA, Tebas P., et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
68.
Shlay JC, Visnegarwala F., Bartsch G., et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine . J Acquir Immune Defic Syndr.2005;38:147-155.
69.
Cameron DW, da Silva B., Arribas J., et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r mono-therapy compared with EFV + ZDV/3TC. In: 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, CA; 2007.
70.
Dubé MP , Komarow L., Mulligan K., et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr.2007 ;45:508-514.
71.
Podzamczer D., Ferrer E., Sanchez P., et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-147.
Barragan P. , Fisac C., Podzamczer D.Switching strategies to improve lipid profile and morphologic changes. AIDS Rev . 2006;8:191-203.
74.
Tebas P., Zhang J., Yarasheski K., et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr. 2007;45:193-200.
75.
Murphy R., Zhang J., Hafner R., et al. Peripheral and visceral fat changes following a treatment switch to a nonthymidine analog or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48 week final results of ACTG A5110, a prospective, randomized, multicenter clinical trial. In: 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO; 2006.
76.
Hultman CS, McPhail LE, Donaldson JH, Wohl DASurgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy . Ann Plast Surg. 2007;58:255-263.
77.
Mest DR, Humble G.Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg . 2006;32: 1336-1345.
78.
Silvers SL, Eviatar JA, Echavez MI, Pappas ALProspective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg.2006;118(suppl 3):34S-45S.
79.
Radiesse. Prescribing Information. San Mateo, CA: BioForm Medical, Inc; 2006.
Carey D., Baker D., Easey N., et al. Poly-L-lactic acid injections for facial lipoatrophy: A randomized, multicenter trial. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007.
82.
Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., Grinspoon S.Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000;284:472-477.
83.
Mulligan K. , Yang Y., Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio . AIDS. 2007;21:47-57.
84.
Kotler DP, Muurahainen N., Grunfeld C., et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239-252.
85.
Vigano A., Mora S., Manzoni P., et al. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents. J Clin Endocrinol Metab. 2005;90:4075-4080.
86.
Falutz J., Allas S., Kotler D., et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation . AIDS. 2005;19:1279-1287.
87.
Falutz J., Allas S., Blot K., et al. Effects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation: a multicenter, double-blind placebo-controlled trial with 412 randomized patients. In: 14th Conference on Retroviruses and Opportunistic Infections (CROI) . Los Angeles, CA; 2007.
88.
Bhasin S., Parker RA, Sattler F., et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049-1057.
89.
Carr A., Workman C., Carey D., et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet . 2004;363: 429-438.
90.
Mallon PW, Miller J., Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS. 2006;20:1003-1010.
91.
Sutinen J., Walker UA, Sevastianova K., et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther. 2007;12: 97-105.
92.
Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
93.
Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS. 2006;20:1843-1850.
94.
Thoni GJ, Fedou C., Brun JF, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab. 2002;28:397-404.
